Hlozek J, Pekova B, Rotnagl J, Holy R, Astl J
Biomedicines. 2022; 10(7).
PMID: 35884820
PMC: 9312840.
DOI: 10.3390/biomedicines10071515.
Rashid F, Bhat G, Khan M, Tabassum S, Bhat M
Mol Clin Oncol. 2022; 16(2):45.
PMID: 35003743
PMC: 8739702.
DOI: 10.3892/mco.2021.2478.
Pitsava G, Stratakis C, Faucz F
Cancers (Basel). 2021; 13(15).
PMID: 34359735
PMC: 8345073.
DOI: 10.3390/cancers13153834.
Paulsson J, Wang N, Gao J, Stenman A, Zedenius J, Mu N
Endocr Relat Cancer. 2020; 27(5):295-308.
PMID: 32163919
PMC: 7159166.
DOI: 10.1530/ERC-19-0446.
Jeong S, Hong H, Lee E, Kwak J, Lee J
Endocrinol Diabetes Metab. 2019; 1(4):e00040.
PMID: 30815568
PMC: 6354824.
DOI: 10.1002/edm2.40.
New Treatment Options for Metastatic Thyroid Cancer.
Kunadharaju R, Goyal G, Rudraraju A, Silberstein P
Fed Pract. 2019; 32(Suppl 7):21S-26S.
PMID: 30766126
PMC: 6375431.
Coding Molecular Determinants of Thyroid Cancer Development and Progression.
Valvo V, Nucera C
Endocrinol Metab Clin North Am. 2019; 48(1):37-59.
PMID: 30717910
PMC: 6366338.
DOI: 10.1016/j.ecl.2018.10.003.
Identification of a novel variant and its association with papillary thyroid carcinoma.
Dou R, Zhang L, Lu T, Liu D, Mei F, Huang J
Oncol Lett. 2018; 15(4):4511-4516.
PMID: 29556290
PMC: 5844012.
DOI: 10.3892/ol.2018.7818.
Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum G, Morkos M, Kim B, Arafat W
Mol Cancer. 2018; 17(1):51.
PMID: 29455653
PMC: 5817719.
DOI: 10.1186/s12943-018-0786-0.
Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.
Siraj A, Masoodi T, Bu R, Beg S, Al-Sobhi S, Al-Dayel F
Am J Hum Genet. 2016; 98(6):1170-1180.
PMID: 27236916
PMC: 4908175.
DOI: 10.1016/j.ajhg.2016.04.014.
Selective use of sorafenib in the treatment of thyroid cancer.
Pitoia F, Jerkovich F
Drug Des Devel Ther. 2016; 10:1119-31.
PMID: 27042004
PMC: 4795584.
DOI: 10.2147/DDDT.S82972.
Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings.
Jeong S, Hong H, Kwak J, Lee E
J Endocrinol Invest. 2015; 38(8):849-57.
PMID: 25999051
DOI: 10.1007/s40618-015-0311-x.
Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved.
Vizioli M, Santos J, Pilotti S, Mazzoni M, Anania M, Miranda C
Oncotarget. 2014; 5(18):8270-83.
PMID: 25268744
PMC: 4226682.
DOI: 10.18632/oncotarget.2013.
Molecular approaches to thyroid cancer diagnosis.
Hsiao S, Nikiforov Y
Endocr Relat Cancer. 2014; 21(5):T301-13.
PMID: 24829266
PMC: 4160369.
DOI: 10.1530/ERC-14-0166.
Deregulation of microRNA expression in thyroid neoplasias.
Pallante P, Battista S, Pierantoni G, Fusco A
Nat Rev Endocrinol. 2013; 10(2):88-101.
PMID: 24247220
DOI: 10.1038/nrendo.2013.223.
Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues.
Pfeifer A, Wojtas B, Oczko-Wojciechowska M, Kukulska A, Czarniecka A, Eszlinger M
BMC Med Genomics. 2013; 6:38.
PMID: 24099521
PMC: 3852913.
DOI: 10.1186/1755-8794-6-38.
DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy.
Keller S, Angrisano T, Florio E, Pero R, Decaussin-Petrucci M, Troncone G
Oncol Lett. 2013; 6(1):86-90.
PMID: 23946782
PMC: 3742793.
DOI: 10.3892/ol.2013.1312.
Genetics and epigenetics of sporadic thyroid cancer.
Vu-Phan D, Koenig R
Mol Cell Endocrinol. 2013; 386(1-2):55-66.
PMID: 23933154
PMC: 3867574.
DOI: 10.1016/j.mce.2013.07.030.
RAS mutations in thyroid cancer.
Howell G, Hodak S, Yip L
Oncologist. 2013; 18(8):926-32.
PMID: 23873720
PMC: 3755930.
DOI: 10.1634/theoncologist.2013-0072.
Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (case-control study).
Khan M, Pandith A, Hussain M, Iqbal M, Khan N, Wani K
Tumour Biol. 2012; 34(1):521-9.
PMID: 23150177
DOI: 10.1007/s13277-012-0577-y.